Trial

NCT04720261

Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University Hospital, Rouen
Collaborators
Condition
Thrombotic Thrombocytopenic Purpura, Acquired
Intervention
Caplacizumab
Why stopped
Recommendations of the independent oversight committee.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20